Telix Pharmaceuticals Beheer
Beheer criteriumcontroles 4/4
Telix Pharmaceuticals' CEO is Chris Behrenbruch, appointed in Jul 2023, has a tenure of 1.33 years. total yearly compensation is A$1.02M, comprised of 49% salary and 51% bonuses, including company stock and options. directly owns 6.97% of the company’s shares, worth A$500.41M. The average tenure of the management team and the board of directors is 2.2 years and 7.2 years respectively.
Belangrijke informatie
Chris Behrenbruch
Algemeen directeur
AU$1.0m
Totale compensatie
Percentage CEO-salaris | 49.0% |
Dienstverband CEO | 1.3yrs |
Eigendom CEO | 7.0% |
Management gemiddelde ambtstermijn | 2.2yrs |
Gemiddelde ambtstermijn bestuur | 7.2yrs |
Recente managementupdates
Recent updates
Analyse CEO-vergoeding
Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
---|---|---|---|
Jun 30 2024 | n/a | n/a | AU$49m |
Mar 31 2024 | n/a | n/a | AU$32m |
Dec 31 2023 | AU$1m | AU$499k | AU$5m |
Sep 30 2023 | n/a | n/a | -AU$21m |
Jun 30 2023 | n/a | n/a | -AU$48m |
Mar 31 2023 | n/a | n/a | -AU$77m |
Dec 31 2022 | AU$865k | AU$422k | -AU$104m |
Sep 30 2022 | n/a | n/a | -AU$111m |
Jun 30 2022 | n/a | n/a | -AU$119m |
Mar 31 2022 | n/a | n/a | -AU$100m |
Dec 31 2021 | AU$620k | AU$374k | -AU$81m |
Sep 30 2021 | n/a | n/a | -AU$70m |
Jun 30 2021 | n/a | n/a | -AU$59m |
Mar 31 2021 | n/a | n/a | -AU$52m |
Dec 31 2020 | AU$421k | AU$295k | -AU$45m |
Sep 30 2020 | n/a | n/a | -AU$40m |
Jun 30 2020 | n/a | n/a | -AU$36m |
Mar 31 2020 | n/a | n/a | -AU$32m |
Dec 31 2019 | AU$460k | AU$317k | -AU$28m |
Sep 30 2019 | n/a | n/a | -AU$23m |
Jun 30 2019 | n/a | n/a | -AU$19m |
Mar 31 2019 | n/a | n/a | -AU$16m |
Dec 31 2018 | AU$380k | AU$280k | -AU$14m |
Sep 30 2018 | n/a | n/a | -AU$12m |
Jun 30 2018 | n/a | n/a | -AU$10m |
Mar 31 2018 | n/a | n/a | -AU$8m |
Dec 31 2017 | AU$303k | AU$211k | -AU$6m |
Compensatie versus markt: Chris's total compensation ($USD667.62K) is below average for companies of similar size in the Australian market ($USD2.23M).
Compensatie versus inkomsten: Chris's compensation has been consistent with company performance over the past year.
CEO
Chris Behrenbruch (48 yo)
1.3yrs
Tenure
AU$1,018,461
Compensatie
Dr. Christian P. Behrenbruch, also known as Chris, BEng (Hons), J.D., Ph.D. DPhil (Oxon), MBA (TRIUM), JD (Melb), FIEAust, GAICD, is Co-Founder, Chief Executive Officer and Managing Director of Telix Pharm...
Leiderschapsteam
Naam | Positie | Tenure | Compensatie | Eigendom |
---|---|---|---|---|
Co-Founder | 1.3yrs | AU$1.02m | 6.97% A$ 500.4m | |
Group Chief Financial Officer | 2.3yrs | AU$713.90k | 0.0019% A$ 139.3k | |
Chief Medical Advisor | no data | AU$43.00k | 6.78% A$ 486.4m | |
Group Chief Medical Officer | less than a year | geen gegevens | 0.11% A$ 8.0m | |
Chief Executive Officer of Telix Therapeutics | 3.5yrs | AU$902.90k | 0.060% A$ 4.3m | |
Group Chief Operating Officer | less than a year | geen gegevens | 0.030% A$ 2.1m | |
Chief Scientist | 3.5yrs | AU$167.76k | geen gegevens | |
Chief Information Officer | 1.8yrs | geen gegevens | geen gegevens | |
Senior Vice President of Corporate Communications & Investor Relations | 3.3yrs | geen gegevens | geen gegevens | |
Group General Counsel | 2.2yrs | geen gegevens | geen gegevens | |
Vice President of Sales | no data | geen gegevens | geen gegevens | |
Senior Vice President of Global People & Culture | 2.2yrs | geen gegevens | geen gegevens |
2.2yrs
Gemiddelde duur
53.5yo
Gemiddelde leeftijd
Ervaren management: TLX's management team is considered experienced (2.2 years average tenure).
Bestuursleden
Naam | Positie | Tenure | Compensatie | Eigendom |
---|---|---|---|---|
Co-Founder | 7.8yrs | AU$1.02m | 6.97% A$ 500.4m | |
Independent Non-Executive Chairman | 7.2yrs | AU$188.28k | 0.34% A$ 24.7m | |
Member of the Scientific Advisory Board | no data | geen gegevens | geen gegevens | |
Member of the Scientific Advisory Board | no data | geen gegevens | geen gegevens | |
Member of the Scientific Advisory Board | no data | geen gegevens | geen gegevens | |
Independent Non-Executive Director | 7.2yrs | AU$103.30k | 1.08% A$ 77.8m | |
Independent Non-Executive Director | 6.4yrs | AU$111.56k | 0.18% A$ 12.8m | |
Member of the Scientific Advisory Board | no data | geen gegevens | geen gegevens | |
Member of the Scientific Advisory Board | no data | geen gegevens | geen gegevens | |
Member of the Scientific Advisory Board | no data | geen gegevens | geen gegevens | |
Member of the Scientific Advisory Board | no data | geen gegevens | geen gegevens | |
Member of the Scientific Advisory Board | no data | geen gegevens | geen gegevens |
7.2yrs
Gemiddelde duur
65yo
Gemiddelde leeftijd
Ervaren bestuur: TLX's board of directors are considered experienced (7.2 years average tenure).